| Year |
Citation |
Score |
| 2022 |
Arciniegas Ruiz S, Rippin I, Eldar-Finkelman H. Prospects in GSK-3 Signaling: From Cellular Regulation to Disease Therapy. Cells. 11. PMID 35626655 DOI: 10.3390/cells11101618 |
0.359 |
|
| 2020 |
Avrahami L, Paz R, Dominko K, Hecimovic S, Bucci C, Eldar-Finkelman H. GSK-3-TSC axis governs lysosomal acidification through autophagy and endocytic pathways. Cellular Signalling. 109597. PMID 32173369 DOI: 10.1016/j.cellsig.2020.109597 |
0.355 |
|
| 2016 |
Eldar-Finkelman H, VanHook AM. Science Signaling Podcast for 15 November 2016: A new type of kinase inhibitor. Science Signaling. 9: pc22. PMID 27902446 DOI: 10.1126/Scisignal.Aal2621 |
0.423 |
|
| 2016 |
Grieco SF, Velmeshev D, Magistri M, Eldar-Finkelman H, Faghihi MA, Jope RS, Beurel E. Ketamine up-regulates a cluster of intronic miRNAs within the serotonin receptor 2C gene by inhibiting glycogen synthase kinase-3. The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry. 1-12. PMID 27723376 DOI: 10.1080/15622975.2016.1224927 |
0.352 |
|
| 2014 |
Azoulay-Alfaguter I, Elya R, Avrahami L, Katz A, Eldar-Finkelman H. Combined regulation of mTORC1 and lysosomal acidification by GSK-3 suppresses autophagy and contributes to cancer cell growth. Oncogene. PMID 25500539 DOI: 10.1038/onc.2014.390 |
0.367 |
|
| 2012 |
Licht-Murava A, Eldar-Finkelman H. Exploiting substrate recognition for selective inhibition of protein kinases. Current Pharmaceutical Design. 18: 2914-20. PMID 22571660 |
0.374 |
|
| 2012 |
Lo Monte F, Kramer T, Gu J, Anumala UR, Marinelli L, La Pietra V, Novellino E, Franco B, Demedts D, Van Leuven F, Fuertes A, Dominguez JM, Plotkin B, Eldar-Finkelman H, Schmidt B. Identification of glycogen synthase kinase-3 inhibitors with a selective sting for glycogen synthase kinase-3α. Journal of Medicinal Chemistry. 55: 4407-24. PMID 22533818 DOI: 10.1021/jm300309a |
0.316 |
|
| 2011 |
Alon LT, Pietrokovski S, Barkan S, Avrahami L, Kaidanovich-Beilin O, Woodgett JR, Barnea A, Eldar-Finkelman H. Selective loss of glycogen synthase kinase-3α in birds reveals distinct roles for GSK-3 isozymes in tau phosphorylation. Febs Letters. 585: 1158-62. PMID 21419127 DOI: 10.1016/J.Febslet.2011.03.025 |
0.361 |
|
| 2010 |
Karyo R, Eskira Y, Pinhasov A, Belmaker R, Agam G, Eldar-Finkelman H. Identification of eukaryotic elongation factor-2 as a novel cellular target of lithium and glycogen synthase kinase-3. Molecular and Cellular Neurosciences. 45: 449-55. PMID 20708687 DOI: 10.1016/j.mcn.2010.08.004 |
0.339 |
|
| 2010 |
Leng S, Zhang W, Zheng Y, Liberman Z, Rhodes CJ, Eldar-Finkelman H, Sun XJ. Glycogen synthase kinase 3 beta mediates high glucose-induced ubiquitination and proteasome degradation of insulin receptor substrate 1. The Journal of Endocrinology. 206: 171-81. PMID 20466847 DOI: 10.1677/Joe-09-0456 |
0.468 |
|
| 2010 |
Eldar-Finkelman H, Licht-Murava A, Pietrokovski S, Eisenstein M. Substrate competitive GSK-3 inhibitors - strategy and implications. Biochimica Et Biophysica Acta. 1804: 598-603. PMID 19770076 DOI: 10.1016/j.bbapap.2009.09.010 |
0.33 |
|
| 2009 |
Eldar-Finkelman H, Eisenstein M. Peptide inhibitors targeting protein kinases. Current Pharmaceutical Design. 15: 2463-70. PMID 19601843 DOI: 10.2174/138161209788682253 |
0.411 |
|
| 2008 |
Ilouz R, Pietrokovski S, Eisenstein M, Eldar-Finkelman H. New insights into the autoinhibition mechanism of glycogen synthase kinase-3beta. Journal of Molecular Biology. 383: 999-1007. PMID 18793648 DOI: 10.1016/j.jmb.2008.08.079 |
0.41 |
|
| 2008 |
Liberman Z, Plotkin B, Tennenbaum T, Eldar-Finkelman H. Coordinated phosphorylation of insulin receptor substrate-1 by glycogen synthase kinase-3 and protein kinase C betaII in the diabetic fat tissue. American Journal of Physiology. Endocrinology and Metabolism. 294: E1169-77. PMID 18430969 DOI: 10.1152/ajpendo.00050.2008 |
0.564 |
|
| 2008 |
Sharfi H, Eldar-Finkelman H. Sequential phosphorylation of insulin receptor substrate-2 by glycogen synthase kinase-3 and c-Jun NH2-terminal kinase plays a role in hepatic insulin signaling. American Journal of Physiology. Endocrinology and Metabolism. 294: E307-15. PMID 18029441 DOI: 10.1152/ajpendo.00534.2007 |
0.565 |
|
| 2007 |
Spalding A, Watson R, Zielske S, Kim A, Bommer G, Fearon E, Eldar-Finkelman H, Lawrence T, Ben-Josef E. Glycogen Synthase Kinase 3β Inhibition and βcatenin Activation Contribute to Enhanced Survival After Radiation in Pancreatic Cancer Cells International Journal of Radiation Oncology*Biology*Physics. 69: S608. DOI: 10.1016/J.Ijrobp.2007.07.1918 |
0.308 |
|
| 2006 |
Kaidanovich-Beilin O, Eldar-Finkelman H. Peptides targeting protein kinases: strategies and implications. Physiology (Bethesda, Md.). 21: 411-8. PMID 17119154 DOI: 10.1152/physiol.00022.2006 |
0.409 |
|
| 2006 |
Ilouz R, Kowalsman N, Eisenstein M, Eldar-Finkelman H. Identification of novel glycogen synthase kinase-3beta substrate-interacting residues suggests a common mechanism for substrate recognition. The Journal of Biological Chemistry. 281: 30621-30. PMID 16893889 DOI: 10.1074/jbc.M604633200 |
0.364 |
|
| 2006 |
Eldar-Finkelman H. Glycogen synthase kinase-3--a promising therapeutic target: Dr Hagit Eldar-Finkelman interviewed by Emma Quigley. Expert Opinion On Therapeutic Targets. 10: 199-201. PMID 16548769 DOI: 10.1517/14728222.10.2.199 |
0.345 |
|
| 2006 |
Kaidanovich-Beilin O, Eldar-Finkelman H. Long-term treatment with novel glycogen synthase kinase-3 inhibitor improves glucose homeostasis in ob/ob mice: molecular characterization in liver and muscle. The Journal of Pharmacology and Experimental Therapeutics. 316: 17-24. PMID 16169938 DOI: 10.1124/jpet.105.090266 |
0.352 |
|
| 2005 |
Liberman Z, Eldar-Finkelman H. Serine 332 phosphorylation of insulin receptor substrate-1 by glycogen synthase kinase-3 attenuates insulin signaling. The Journal of Biological Chemistry. 280: 4422-8. PMID 15574412 DOI: 10.1074/jbc.M410610200 |
0.534 |
|
| 2005 |
Talior I, Tennenbaum T, Kuroki T, Eldar-Finkelman H. PKC-delta-dependent activation of oxidative stress in adipocytes of obese and insulin-resistant mice: role for NADPH oxidase. American Journal of Physiology. Endocrinology and Metabolism. 288: E405-11. PMID 15507533 DOI: 10.1152/ajpendo.00378.2004 |
0.368 |
|
| 2004 |
Kirshenboim N, Plotkin B, Shlomo SB, Kaidanovich-Beilin O, Eldar-Finkelman H. Lithium-mediated phosphorylation of glycogen synthase kinase-3beta involves PI3 kinase-dependent activation of protein kinase C-alpha. Journal of Molecular Neuroscience : Mn. 24: 237-45. PMID 15456937 DOI: 10.1385/JMN:24:2:237 |
0.432 |
|
| 2003 |
Eldar-Finkelman H, Ilouz R. Challenges and opportunities with glycogen synthase kinase-3 inhibitors for insulin resistance and Type 2 diabetes treatment. Expert Opinion On Investigational Drugs. 12: 1511-9. PMID 12943495 DOI: 10.1517/13543784.12.9.1511 |
0.421 |
|
| 2003 |
Talior I, Yarkoni M, Bashan N, Eldar-Finkelman H. Increased glucose uptake promotes oxidative stress and PKC-delta activation in adipocytes of obese, insulin-resistant mice. American Journal of Physiology. Endocrinology and Metabolism. 285: E295-302. PMID 12857675 DOI: 10.1152/ajpendo.00044.2003 |
0.302 |
|
| 2003 |
Plotkin B, Kaidanovich O, Talior I, Eldar-Finkelman H. Insulin mimetic action of synthetic phosphorylated peptide inhibitors of glycogen synthase kinase-3. The Journal of Pharmacology and Experimental Therapeutics. 305: 974-80. PMID 12626660 DOI: 10.1124/jpet.102.047381 |
0.429 |
|
| 2002 |
Kaidanovich O, Eldar-Finkelman H. The role of glycogen synthase kinase-3 in insulin resistance and type 2 diabetes. Expert Opinion On Therapeutic Targets. 6: 555-61. PMID 12387679 DOI: 10.1517/14728222.6.5.555 |
0.499 |
|
| 2002 |
Ilouz R, Kaidanovich O, Gurwitz D, Eldar-Finkelman H. Inhibition of glycogen synthase kinase-3beta by bivalent zinc ions: insight into the insulin-mimetic action of zinc. Biochemical and Biophysical Research Communications. 295: 102-6. PMID 12083774 DOI: 10.1016/S0006-291X(02)00636-8 |
0.397 |
|
| 2002 |
Eldar-Finkelman H. Glycogen synthase kinase 3: an emerging therapeutic target. Trends in Molecular Medicine. 8: 126-32. PMID 11879773 DOI: 10.1016/S1471-4914(01)02266-3 |
0.356 |
|
| 2000 |
Zhao AZ, Shinohara MM, Huang D, Shimizu M, Eldar-Finkelman H, Krebs EG, Beavo JA, Bornfeldt KE. Leptin induces insulin-like signaling that antagonizes cAMP elevation by glucagon in hepatocytes. The Journal of Biological Chemistry. 275: 11348-54. PMID 10753948 DOI: 10.1074/Jbc.275.15.11348 |
0.589 |
|
| 1999 |
Eldar-Finkelman H, Schreyer SA, Shinohara MM, LeBoeuf RC, Krebs EG. Increased glycogen synthase kinase-3 activity in diabetes- and obesity-prone C57BL/6J mice. Diabetes. 48: 1662-6. PMID 10426388 DOI: 10.2337/Diabetes.48.8.1662 |
0.514 |
|
| 1999 |
Torres MA, Eldar-Finkelman H, Krebs EG, Moon RT. Regulation of ribosomal S6 protein kinase-p90(rsk), glycogen synthase kinase 3, and beta-catenin in early Xenopus development. Molecular and Cellular Biology. 19: 1427-37. PMID 9891076 DOI: 10.1128/Mcb.19.2.1427 |
0.561 |
|
| 1997 |
Eldar-Finkelman H, Krebs EG. Phosphorylation of insulin receptor substrate 1 by glycogen synthase kinase 3 impairs insulin action. Proceedings of the National Academy of Sciences of the United States of America. 94: 9660-4. PMID 9275179 DOI: 10.1073/pnas.94.18.9660 |
0.626 |
|
| 1996 |
Eldar-Finkelman H, Argast GM, Foord O, Fischer EH, Krebs EG. Expression and characterization of glycogen synthase kinase-3 mutants and their effect on glycogen synthase activity in intact cells. Proceedings of the National Academy of Sciences of the United States of America. 93: 10228-33. PMID 8816781 DOI: 10.1073/Pnas.93.19.10228 |
0.583 |
|
| 1995 |
Eldar-Finkelman H, Seger R, Vandenheede JR, Krebs EG. Inactivation of glycogen synthase kinase-3 by epidermal growth factor is mediated by mitogen-activated protein kinase/p90 ribosomal protein S6 kinase signaling pathway in NIH/3T3 cells. The Journal of Biological Chemistry. 270: 987-90. PMID 7836418 DOI: 10.1074/Jbc.270.3.987 |
0.636 |
|
| 1994 |
Seger R, Seger D, Reszka AA, Munar ES, Eldar-Finkelman H, Dobrowolska G, Jensen AM, Campbell JS, Fischer EH, Krebs EG. Overexpression of mitogen-activated protein kinase kinase (MAPKK) and its mutants in NIH 3T3 cells. Evidence that MAPKK involvement in cellular proliferation is regulated by phosphorylation of serine residues in its kinase subdomains VII and VIII. The Journal of Biological Chemistry. 269: 25699-709. PMID 7929275 |
0.635 |
|
| Show low-probability matches. |